Global Depressive Disorder Market to Grow in the Offing, States Koncept Analytics in Its Cutting-Edge Report Recently Added at MarketPublishers.com
31 Aug 2016 • by Natalie Aster
LONDON – The worldwide depressive disorder market is anticipated to witness positive growth in the years to come and to overcome declining revenues owing to patent expiry and introduction of better innovative therapies and drugs.
The highest prevalence of depression disorder and also bipolar depression and schizophrenia is registered in the US. Due to enhancing awareness along with expanding access to medical facilities, the depressive disorder market is anticipated to enjoy remarkable growth across the globe, especially in the APAC region.
Major factors propelling growth in the depressive disorder market includes increasing healthcare expenditures, rising smoking prevalence, increasing female population, surging number of prescription drugs and enhancing spending on medicines, among others. At the same time, some factors like tough regulations, patent expiry and severe side effects of drugs could restrain growth in the depressive disorder market.
The new research publication “Global Depressive Disorder Market: Industry Analysis & Outlook (2016-2020)” issued by Koncept Analytics gives info on the current state of the worldwide depressive disorder market, explores the market dynamics, scrutinises the key factors shaping the market and examines the top development trends. It touches upon scenario across the main geographical markets, describes competitive pressures, discusses the hottest industry issues and also gives info on top market players (including Lundbeck, Pfizer, AstraZeneca, Eli Lilly and company).
More reports by Koncept Analytics is offered at this page.